Mesoblast (ASX:MSB) share price tumbles 8% giving back most of yesterday's gains

What's happened to the company's shares?

| More on:
a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price was in reverse today after surging more than 11% on Monday. The allogeneic cellular medicines company announced a trial update to its rexlemestrocel-L drug.

At the closing bell, Mesoblast shares finished the day down 8.68% to $1.735.

Why are Mesoblast shares falling?

Investors appeared to be taking profit off the table, sending the Mesoblast share price lower.

Following yesterday's astronomical gains, trading volumes rocketed to levels not seen since early September.

The company provided results from its phase 3 trial of rexlemestrocel-l in 565 patients suffering from chronic heart failure.

Presented at the American Heart Association (AHA) annual Scientific Sessions, Mesoblast highlighted a key takeaway from the landmark study. This related to the significant relationship between the presence of systemic inflammation and the treatment benefit with rexlemestrocel-L.

In particular, a single dose of rexlemestrocel-L, along with standard of care, reduced the incidence of heart attacks or strokes by 65% across all patients. This figure is compared against standard of care alone.

In addition, the same dosage of rexlemestrocel-L with standard of care diminished the incidence of cardiovascular death, heart attacks, or strokes by 33%.

How does rexlemestrocel-L work?

Rexlemestrocel-L reduces inflammatory cytokine production by immune cells, generating improved local networks of blood vessels within the damaged heart. In turn, this lowers the risk of plaque rupture in major arteries.

Heart failure affects around 6.5 million people in the United States and 26 million people globally, with rates increasing every year. The mortality rate approaches 50% at 5 years as patients progress beyond New York Heart Association (NYHA) class II disease.

Mesoblast share price summary

In the past 12 months, Mesoblast shares have disappointed investor expectations, failing to take off. The company's share price is down by almost 50% since this time last year, and down almost 23% year-to-date.

It's worth noting that Mesoblast shares are a long way off their 52-week high of $5.05.

Based on today's price, Mesoblast presides a market capitalisation of around $1.13 billion, with approximately 648.7 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »